Yahoo Web Search

  1. The 52-week phase III study FINCH 1 evaluated filgotinib compared to AbbVie's ABBV Humira (adalimumab) or placebo on a stable background dose of methotrexate (MTX) in patients with prior inadequate ...

  2. FDA approves new treatment for patients with migraine

    PR Newswire via Yahoo FinanceOct 11 18:28 PM

    SILVER SPRING, Md., Oct. 11, 2019 /PRNewswire/ -- The U.S. Food and Drug Administration today approved Reyvow (lasmiditan) tablets for the acute (active but short-term) treatment of migraine ...

  3. Hedge Funds Are Selling Royal Bank of Canada (RY)

    Insider Monkey via Yahoo FinanceOct 10 13:55 PM

    Our calculations also showed that RY isn't among the 30 most popular stocks among hedge funds (see the video at the end of this article). Today there are several formulas market participants ...

  4. Verastem's (VSTM) Copiktra Gets Orphan Drug Designation

    Zacks via Yahoo FinanceOct 08 14:02 PM

    Verastem, Inc. VSTM announced that the FDA has granted orphan drug designation to Copiktra (duvelisib) for the treatment of T-Cell lymphoma. The drug already enjoys Fast Track designation for this indication.

  5. The company is evaluating IPI-549 as a monotherapy and in combination with Bristol-Myers Squibb's BMY Opdivo in a phase I/Ib study (MARIO-1) in about 200 patients with advanced solid tumors.

  6. While big names like Pfizer, Bristol-Myers and Lilly performed relatively poorly, Amgen, AstraZeneca, AbbVie, Sanofi and Merck delivered decent earnings and sales growth. It is to be ...

  7. Is Amgen, Inc. (AMGN) A Good Stock To Buy According To Hedge Funds?

    Insider Monkey via Yahoo FinanceOct 09 20:46 PM

    Investing in hedge funds can bring large profits, but it’s not for everybody, since hedge funds are available only for high-net-worth individuals. A particularly interesting group of stocks ...

  8. Drugmakers over the last two years raised prices on seven widely used medications above the rate of medical inflation and without any new clinical evidence to justify the increases, according ...

  9. BioNTech IPO: What You Need To Know

    Benzinga via Yahoo FinanceOct 08 11:55 AM

    The company expects to price the offering between $18 and $20 per ADS. At the midpoint of the estimated price range, the size of the offering is likely to be $250.8 million. The company has ...

  10. This week, the FDA approved Novartis' NVS potential blockbuster eye drug, Beovu. J&J JNJ submitted a regulatory application seeking label expansion approval of its plaque psoriasis drug, Stelara ...

  1. Ads
    related to Eli Lilly